WARNING: FETAL TOXICITY
- When pregnancy is detected, discontinue ATACAND as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].
- Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning.
- When pregnancy is detected, discontinue ATACAND as soon as possible. (5.1, 8.1)
- Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1, 8.1)
Use: Labeled indications
- Treatment of hypertension in adults and children 1 to < 17 years of age, to lower blood pressure.
- Treatment of heart failure (NYHA class II-IV); ATACAND reduces cardiovascular death and heart failure hospitalization
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ATACAND is an angiotensin II receptor blocker (ARB) indicated for:
- Treatment of hypertension in adults and children 1 to < 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1).
- Treatment of heart failure (NYHA class II-IV); ATACAND reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension ATACAND is indicated for the treatment of hypertension in adults and in children 1 to <17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. ATACAND may be used alone or in combination with other antihypertensive agents. 1.2 Heart Failure ATACAND is indicated for the treatment of heart failure (NYHA class II-IV) in adults with left ventricular systolic dysfunction (ejection fraction ≤ 40%) to reduce cardiovascular death and to reduce heart failure hospitalizations [see Clinical Studies (14.2)]. ATACAND also has an added effect on these outcomes when used with an ACE inhibitor [see Drug Interactions (7.4)].
Contraindications
4 CONTRAINDICATIONS ATACAND is contraindicated in patients who are hypersensitive to candesartan. Do not co-administer aliskiren with ATACAND in patients with diabetes [see Drug Interactions (7.4)]. Known hypersensitivity to product components (4). Do not co-administer aliskiren with ATACAND in patients with diabetes (4).
US FDA labelDosing: Adult
- Starting Dose Target Dose Adult Hypertension (2.1)
- 16 mg tablet once daily 8 – 32 mg tablet total daily dose Pediatric Hypertension (1 to < 6 years) (2.2)
- 0.20 mg/kg oral suspension once daily 0.05 – 0.4 mg/kg oral suspension once daily or consider divided dose Pediatric Hypertension (6 to < 17 years) (2.2)
- < 50 kg 4 – 8 mg tablet once daily >50 kg 8 – 16 mg tablet once daily < 50 kg 4 – 16 mg tablet once daily or consider divided dose > 50 kg 4 – 32 mg tablet once daily or consider divided dose Adult Heart Failure (2.3)
- 4 mg tablet once daily 32 mg tablet once daily The target dose is 32 mg once daily, which is achieved by doubling the dose at approximately 2-week intervals, as tolerated by patient.
2.1 Adult Hypertension
2.1 Adult Hypertension Dosage must be individualized. Blood pressure response is dose related over the range of 2 to 32 mg. The usual recommended starting dose of ATACAND is 16 mg once daily when it is used as monotherapy in patients who are not volume depleted. ATACAND can be administered once or twice daily with total daily doses ranging from 8 mg to 32 mg.
Larger doses do not appear to have a greater effect, and there is relatively little experience with such doses. Most of the antihypertensive effect is present within 2 weeks, and maximal blood pressure reduction is generally obtained within 4 to 6 weeks of treatment with ATACAND. Use in Hepatic Impairment: Initiate with 8 mg ATACAND in patients with moderate hepatic insufficiency.
Dosing recommendations cannot be provided for patients with severe hepatic insufficiency [see Clinical Pharmacology (12.3)]. ATACAND may be administered with or without food. If blood pressure is not controlled by ATACAND alone, a diuretic may be added. ATACAND may be administered with other antihypertensive agents.
2.2 Pediatric Hypertension 1
2.2 Pediatric Hypertension 1 to < 17 Years of Age ATACAND may be administered once daily or divided into two equal doses. Adjust the dosage according to blood pressure response. For patients with possible depletion of intravascular volume (e.g., patients treated with diuretics, particularly those with impaired renal function), initiate ATACAND under close medical supervision and consider administration of a lower dose [see Warnings and Precautions (5.3)].
Children 1 to < 6 years of age: The dose range is 0.05 to 0.4 mg/kg per day. The recommended starting dose is 0.20 mg/kg (oral suspension). Children 6 to < 17 years of age: For those less than 50 kg, the dose range is 2 to 16 mg per day. The recommended starting dose is 4 to 8 mg. For those greater than 50 kg, the dose range is 4 to 32 mg per day.
The recommended starting dose is 8 to 16 mg. Doses above 0.4 mg/kg (1 to < 6 year olds) or 32 mg (6 to < 17 year olds) have not been studied in pediatric patients [see Clinical Studies (14.1)]. An antihypertensive effect is usually present within 2 weeks, with full effect generally obtained within 4 weeks of treatment with ATACAND.
Children < 1 year of age must not receive ATACAND for hypertension. All pediatric patients with a glomerular filtration rate less than 30 mL/min/1.73 m² should not receive ATACAND since ATACAND has not been studied in this population [see Use in Specific Populations (8.4)]. For children who cannot swallow tablets, an oral suspension may be substituted as described below: Preparation of Oral Suspension: ATACAND oral suspension can be prepared in concentrations within the range of 0.1 to 2.0 mg/mL.
Typically, a concentration of 1 mg/mL will be suitable for the prescribed dose. Any strength of ATACAND tablets can be used in the preparation of the suspension. Follow the steps below for preparation of the suspension. The number of tablets and volume of vehicle specified below will yield 160 mL of a 1 mg/mL suspension.
- Prepare the vehicle by adding equal volumes of Ora-Plus ® (80 mL) and Ora-Sweet SF ® (80 mL) or, alternatively, use Ora-Blend SF ® (160 mL).
- Add a small amount of vehicle to the required number of ATACAND tablets (five 32 mg tablets) and grind into a smooth paste using a mortar and pestle.
- Add the paste to a preparation vessel of suitable size.
- Rinse the mortar and pestle clean using the vehicle and add this to the vessel. Repeat, if necessary.
- Prepare the final volume by adding the remaining vehicle.
- Mix thoroughly.
- Dispense into suitably sized amber PET bottles.
- Label with an expiry date of 100 days and include the following instructions: Store at room temperature (below 30°C/86°F). Use within 30 days after first opening. Do not use after the expiry date stated on the bottle. Do not freeze. Shake well before each use.
2.3 Adult Heart Failure
2.3 Adult Heart Failure The recommended initial dose for treating heart failure is 4 mg once daily. The target dose is 32 mg once daily, which is achieved by doubling the dose at approximately 2-week intervals, as tolerated by the patient.
Dosing: Altered kidney function
Renal Insufficiency In hypertensive patients with renal insufficiency, serum concentrations of candesartan were elevated. After repeated dosing, the AUC and C max were approximately doubled in patients with severe renal impairment (creatinine clearance <30 mL/min/1.73 m²) compared to patients with normal kidney function.
The pharmacokinetics of candesartan in hypertensive patients undergoing hemodialysis are similar to those in hypertensive patients with severe renal impairment. Candesartan cannot be removed by hemodialysis. No initial dosage adjustment is necessary in patients with renal insufficiency [see Dosage and Administration (2.1)].
In heart failure patients with renal impairment, AUC 0-72h was 36% and 65% higher in mild and moderate renal impairment, respectively. C max was 15% and 55% higher in mild and moderate renal impairment, respectively.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The antihypertensive effects of ATACAND were evaluated in hypertensive children 1 to < 17 years of age in randomized, double-blind clinical studies [see Clinical Studies (14.1)]. The pharmacokinetics of ATACAND have been evaluated in pediatric patients 1 to < 17 years of age [see Clinical Pharmacology (12.3)]. Children < 1 year of age must not receive ATACAND for hypertension [see Warnings and Precautions (5.2)].
Dosage forms
Philippines
- Tablet: 4 mg, 8 mg, 16 mg, 32 mg
Registered products in the Philippines
58 products registered with the Food and Drug Administration (FDA) Philippines list Candesartan as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products58
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Aiiracan 16Candesartan cilexetil | 16mg TabletAlu-alu Blister Pack x 10's (Box of 100' s) | RxVAT-exempt | Unison Laboratories Co., Ltd.Thailand | Justright Healthcare Inc. | DR-XY48801 | Jun 30, 2028 | |
Aiiracan 8Candesartan Cilexetil | 8mg tabletAlu-alu Blister Pack x 10's (Box of 100 's) | RxVAT-exempt | Unison Laboratories Co., LtdThailand | Justright Healthcare Inc. | DR-XY48802 | Jun 30, 2028 | |
AlvopressCandesartan Cilexetil | 32 mg TabletAlu/PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Laboratorios Liconsa, S.A.Spain | Metro Drug, Inc.Trader: Lotus International Pte. Ltd. | DR-XY 47871 | Mar 30, 2027 | |
AtasartCandesartan Cilexetil | 16 mg TabletAlu/Alu Blister Pack x 7’s (Box of 28’s); Alu/Alu Blister Pack x 1’s [Physician's Sample] (Box of 1’s) | RxVAT-exempt | Getz Pharma Pvt. Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY42155 | Feb 12, 2030 | |
AtasartCandesartan Cilexetil | 16 mg TabletAlu / Alu Blister Pack x 7’s (Box of 28's); Alu/Alu Blister Pack x 1’s [Physician's Sample] (Box of 1’s) | RxVAT-exempt | Getz Pharma (Pvt.), Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DRP-15776 | Jul 1, 2028 | |
AtasartCandesartan Cilexetil | 8 mg TabletAlu/Alu Blister Pack x 7's (Box of 28's) Alu/Alu Blister Pack x 1's [Physician's Sample] (Box of 1's) | RxVAT-exempt | Getz Pharma Pvt. Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY42156 | Feb 12, 2030 | |
AtasartCandesartan Cilexetil | 8 mg TabletAlu-Alu Blister Pack x 7’s (Box of 14’s); Alu-Alu Blister Pack x 1's [Physician's Sample] (Box of 1's) | RxVAT-exempt | Getz Pharma (Phils.), Inc.Pakistan | Importer: Getz Pharma (Phil.), Inc. | DRP-15774 | Jul 1, 2028 | |
Babapress-16Candesartan Cilexetil | 16 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-3916 | Aug 14, 2027 | |
Babapress-8Candesartan Cilexetil | 8 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-3915 | Aug 14, 2027 | |
BlopressCandesartan Cilexetil | 16 mg TabletAlu/PVC/PVDC Blister pack x 7's (Box of 7's and 28's) | RxVAT-exempt | Delpharm Novara S.R.L.Italy | Importer: Celltrion Healthcare Philippines, Inc. | DR-XY24549 | Oct 19, 2028 | |
BlopressCandesartan cilexetil | 8mg TabletAlu/PVC/PVDC Blister pack x 7's (Box of 7's and 28's) | RxVAT-exempt | Delpharm Novara S.R.L.Italy | Celltrion Healthcare Philippines, Inc. | DR-XY24550 | Oct 12, 2028 | |
CampertenCandesartan Cilexetil | 4 mg TabletAlu/Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-4611 | Aug 8, 2028 | |
Camperten 16Candesartan Cilexetil | 16 mg TabletAlu/Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-4610 | Aug 8, 2028 | |
Camperten 8Candesartan Cilexetil | 8 mg TabletAlu/Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-4609 | Aug 8, 2028 | |
CandegenCandesartan cilexetil | 16 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lek Pharmaceuticals d.dSlovenia | TGP Pharma Inc.Importer: Sandoz Philippines Corporation | DRP-4365-01 | Apr 8, 2028 | |
Candego-16Candesartan Cilexetil | 16 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation | DRP-3916-02 | Aug 14, 2027 | |
Candego-8Candesartan Cilexetil | 8 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation | DRP-3915-02 | Aug 14, 2032 | |
CandelifeCandesartan Cilexetil | 16 mg TabletAlu/Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Pharmalife DistributionImporter: Ambica International Corporation | DRP-4610-02 | Aug 8, 2028 | |
CandephilCandesartan cilexetil | 16mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-16813 | Jul 15, 2030 | |
CandephilCandesartan cilexetil | 4mg TabletAluminum/aluminum Blister Pack | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-16811 | Jul 15, 2030 | |
CandephilCandesartan cilexetil | 8mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-16812 | Jul 15, 2030 | |
Candesaph-16Candesartan Cilexetil | 16mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-11552 | Mar 29, 2027 | |
Candesaph-8Candesartan cilexetil | 8 mg TabletAlu/Alu Blister pack of 10's (Box of 30's) | RxVAT-exempt | Sai Parenterals LimitedIndia | Nelpa Lifesciences Inc. | DRP-11925 | Sep 9, 2030 | |
Candesaph-GE16Candesartan Cilexetil | 16 mg TabletAlu/Alu Blister pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-18231 | Jun 3, 2031 | |
CandestraCandesartan Cilexetil | 8 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3915-05 | Aug 14, 2027 | |
CandezCandesartan Cilexetil | 16 mg TabletAlu/PVC Blister Pack x 10's Box of 30's | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: Unilab, Inc. | DRP-10065 | May 11, 2029 | |
CandezCandesartan Cilexetil | 8 mg TabletAlu/PVC Blister Pack x 10's Box of 30's | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: Unilab, Inc. | DRP-10064 | May 11, 2029 | |
Caneen 16Candesartan Cilexetil | 16 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-17481 | Jan 12, 2031 | |
Caneen 8Candesartan Cilexetil | 8 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-17482 | Jan 12, 2031 | |
Carexetan-16Candesartan cilexetil | 16 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-11258 | Mar 4, 2027 | |
Carexetan-8Candesartan Cilexetil | 8 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-11257 | Mar 4, 2027 | |
DesarenCandesartan Cilexetil | 8 mg TabletAlu/Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-4609-01 | Aug 8, 2028 | |
FrepanCandesartan cilexetil | 16 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lek Pharmaceuticals D.D.Slovenia | Importer: Sandoz Philippines Corporation | DRP-4365 | Apr 8, 2028 | |
FrepanCandesartan cilexetil | 8 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lek Pharmaceuticals d.d.Slovenia | Importer: Sandoz Philippines Corporation | DRP-4367 | Apr 8, 2028 | |
Giran-16Candesartan (as cilexetil) | 16 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | ARISTOPHARMA LTD.Bangladesh | SAHAR INTERNATIONAL TRADING INC. | DRP-6036 | Jul 20, 2027 | |
Giran-8Candesartan (as cilexetil) | 8 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | ARISTOPHARMA LTD.Bangladesh | SAHAR INTERNATIONAL TRADING INC. | DRP-6257 | Jul 20, 2027 | |
HyperestCandesartan cilexetil | 16 mg TabletAlu/PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Laboratorios Liconsa, S.A.Spain | Metro Drug, Inc. | DR-XY48651 | Mar 24, 2028 | |
HyperestCandesartan cilexetil | 8 mg TabletAlu/PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Laboratorios Liconsa, S.A.Spain | Metro Drug, Inc. | DR-XY 48652 | Mar 24, 2028 | |
Medicand-16Candesartan Cilexetil | 16 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Titan Laboratories Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-17474 | Jan 7, 2031 | |
Medicand-8Candesartan Cilexetil | 8 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Titan Laboratories Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-17473 | Jan 7, 2031 | |
NoneCandesartan cilexetil | 16 mg tabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Watsons Personal Care Store (Philippines), Inc.Importer: Nelpa Lifesciences, Inc. | DRP-11552-02 | May 29, 2027 | |
NoneCandesartan Cilexetil | 16 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-3916-01 | Aug 14, 2027 | |
NoneCandesartan Cilexetil | 16 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-3916-03 | Aug 14, 2027 | |
NoneCandesartan Cilexetil | 16 mg TabletAlu/Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-4610-01 | Aug 8, 2028 | |
NoneCandesartan Cilexetil | 16 mg TabletAlu/Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-4610-03 | Aug 8, 2028 | |
NoneCandesartan (as cilexetil) | 16 mg TabletAlu / Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Aristopharma Ltd.Bangladesh | Watsons Personal Care Stores (Philippines), Inc.Importer: Sahar International Trading Inc. | DRP-6036-01 | Jul 20, 2027 | |
NoneCandesartan Cilexetil | 4 mg TabletAlu/Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-4611-01 | Aug 8, 2028 | |
NoneCandesartan Cilexetil | 8 mg tabletAlu/Alu Blister pack x 10’s (Box of 30’s) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Watsons Personal Care Stores (Philippines), Inc.Importer: Nelpa Lifesciences, Inc. | DRP-11925-01 | May 20, 2027 | |
NoneCandesartan Cilexetil | 8 mg TabletALu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-3915-01 | Aug 14, 2027 | |
NoneCandesartan Cilexetil | 8 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-3915-03 | Aug 14, 2027 | |
NoneCandesartan Cilexetil | 8 mg TabletAlu/Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-4609-02 | Aug 8, 2028 | |
NoneCandesartan Cilexetil | 8 mg TabletAlu/Alu Blister Pack x 7's (Box of 28's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-4609-03 | Aug 8, 2028 | |
NoneCandesartan (as cilexetil) | Tablet 8 mgAlu/ Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Aristopharma Ltd.Bangladesh | Watsons Personal Care Stores (Philippines), Inc.Importer: Sahar International Trading Inc. | DRP-6257-01 | Jul 20, 2027 | |
Redsartan 8Candesartan cilexetil | 8 mg TabletAlu/Alu Blister Pack of 10’s (Box of 30’s) | RxVAT-exempt | Sai Parenterals LimitedTSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India. | 777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-11925-02 | Sep 9, 2030 | |
RetadesartzCandesartan Cilexetil | 16 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Reta DrugImporter: Ambica International Corporation | DRP-3916-04 | Aug 14, 2027 | |
RetadesartzCandesartan Cilexetil | 8 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Reta DrugImporter: Ambica International Corporation | DRP-3915-04 | Aug 14, 2027 | |
Torcand-32Candesartan cilexetil | 32 mg TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY48684 | Mar 31, 2028 | |
Torcand-8Candesartan Cilexetil | 8 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | TORRENT PHARMACEUTICALS LTD.India | TORRENT PHARMA PHILIPPINES INC. | DR-XY41250 | Sep 19, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS 4 mg are white to off-white, circular/biconvex-shaped, non-film-coated scored tablets, coded ACF on one side and 004 on the other. 8 mg are light pink, circular/biconvex-shaped, non-film-coated scored tablets, coded ACG on one side and 008 on the other. 16 mg are pink, circular/biconvex-shaped, non-film-coated scored tablets, coded ACH on one side and 016 on the other. 32 mg are pink, circular/biconvex-shaped, non-film-coated scored tablets, coded ACL on one side and 032 on the other. Tablets 4 mg, 8 mg, 16 mg, 32 mg (3).
Warnings/Precautions
The boxed warning is shown at the top of this page.
- • Observe for signs and symptoms of hypotension (5.3). • Monitor renal function (5.4)
- and potassium levels (5.5).
5.1 Fetal Toxicity
5.1 Fetal Toxicity ATACAND can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations.
Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure and death. When pregnancy is detected, discontinue ATACAND as soon as possible [see Use in Specific Populations (8.1)].
5.2 Morbidity in Infants Children
5.2 Morbidity in Infants Children < 1 year of age must not receive ATACAND for hypertension. Drugs that act directly on the renin-angiotensin system (RAS) can have effects on the development of immature kidneys.
5.3 Hypotension
5.3 Hypotension ATACAND can cause symptomatic hypotension. Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Patients with symptomatic hypotension may require temporarily reducing the dose of ATACAND, diuretic or both, and volume repletion.
Volume and/or salt depletion should be corrected before initiating therapy with ATACAND. In the CHARM program (heart failure patients), hypotension was reported in 18.8% of patients on ATACAND versus 9.8% of patients on placebo. The incidence of hypotension leading to drug discontinuation in ATACAND-treated patients was 4.1% compared with 2.0% in placebo-treated patients.
In the CHARM-Added program, where candesartan or placebo was given in addition to ACE inhibitors, hypotension was reported in 22.6% of patients treated with ATACAND versus 13.8% treated with placebo [see Drug Interactions (7.3)]. Monitoring of blood pressure is recommended during dose escalation and periodically thereafter.
Major Surgery/Anesthesia Hypotension may occur during major surgery and anesthesia in patients treated with angiotensin II receptor antagonists, including ATACAND, due to blockade of the renin-angiotensin system. Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors.
5.4 Impaired Renal Function
5.4 Impaired Renal Function Monitor renal function periodically in patients treated with ATACAND. Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system. Patients whose renal function may depend, in part, on the activity of the renin-angiotensin system (e.g., patient with renal artery stenosis, chronic kidney disease, severe heart failure, or volume depletion) may be at particular risk of developing oliguria, progressive azotemia or acute renal failure when treated with ATACAND.
Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on ATACAND. In the CHARM program (heart failure patients), the incidence of abnormal renal function (e.g., creatinine increase) was 12.5% in patients treated with ATACAND versus 6.3% in patients treated with placebo.
The incidence of abnormal renal function (e.g., creatinine increase) leading to drug discontinuation in ATACAND-treated patients was 6.3% compared with 2.9% in placebo-treated patients. In the CHARM-Added program, where candesartan or placebo was given in addition to ACE inhibitors, the incidence of abnormal renal function (e.g., creatinine increase) was 15% in patients treated with ATACAND versus 9% in patients treated with placebo [see Drug Interactions (7.3)].
5.5 Hyperkalemia
5.5 Hyperkalemia Drugs that inhibit the renin-angiotensin system can cause hyperkalemia. Concomitant use of ATACAND with drugs that increase potassium levels may increase the risk of hyperkalemia [see Drug Interactions (7.1)]. Monitor serum potassium periodically. In the CHARM program (heart failure patients), the incidence of hyperkalemia was 6.3% in patients treated with ATACAND versus 2.1% in patients treated with placebo.
The incidence of hyperkalemia leading to drug discontinuation in ATACAND-treated patients was 2.4% compared with 0.6% in placebo-treated patients. In the CHARM-Added program where candesartan or placebo was given in addition to ACE inhibitors, the incidence of hyperkalemia was 9.5% in patients treated with ATACAND versus 3.5% in patients treated with placebo [see Drug Interactions (7.1)].
Drug interactions
- Lithium: Increases in serum lithium concentrations and toxicity (7).
- NSAIDs use may lead to increased risk of renal impairment and loss of antihypertensive effect (7).
- Combined inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7).
7.1 Agents Increasing Serum Potassium Co-administration
7.1 Agents Increasing Serum Potassium Co-administration of ATACAND with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.
7.2 Lithium
7.2 Lithium Increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists, including ATACAND. Monitor serum lithium levels.
7.3 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors…
7.3 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including candesartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.
Monitor renal function periodically in patients receiving candesartan and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including candesartan may be attenuated by NSAIDs including selective COX-2 inhibitors.
7.4 Combination Blockade of the Renin-Angiotensin System (RAS)
7.4 Combination Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Triple combination of ATACAND with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended.
Closely monitor blood pressure, renal function and electrolytes in patients on ATACAND and other agents that affect the RAS. Do not co-administer aliskiren with ATACAND in patients with diabetes. Avoid use of aliskiren with ATACAND in patients with renal impairment (GFR <60 mL/min) [see Contraindications (4)].
Adverse reactions
- Most common adverse reactions which caused adult patients to discontinue therapy for:
- Hypertension were headache (0.6%) and dizziness (0.3%) (6.1).
- Heart Failure were hypotension (4.1%) (5.3), abnormal renal function (6.3%) (5.4), and hyperkalemia (2.4%) (5.5). To report SUSPECTED ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-855-204-1431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Studies Experience
6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Adult Hypertension ATACAND has been evaluated for safety in more than 3600 patients/subjects, including more than 3200 patients treated for hypertension.
About 600 of these patients were studied for at least 6 months and about 200 for at least 1 year. In general, treatment with ATACAND was well tolerated. The overall incidence of adverse events reported with ATACAND was similar to placebo. The rate of withdrawals due to adverse events in all trials in patients (7510 total) was 3.3% (i.e., 108 of 3260) of patients treated with ATACAND as monotherapy and 3.5% (i.e., 39 of 1106) of patients treated with placebo.
In placebo-controlled trials, discontinuation of therapy due to clinical adverse events occurred in 2.4% (i.e., 57 of 2350) of patients treated with ATACAND and 3.4% (i.e., 35 of 1027) of patients treated with placebo. The most common reasons for discontinuation of therapy with ATACAND were headache (0.6%) and dizziness (0.3%).
The adverse events that occurred in placebo-controlled clinical trials in at least 1% of patients treated with ATACAND and at a higher incidence in candesartan cilexetil (n = 2350) than placebo (n = 1027) patients included back pain (3% vs. 2%), dizziness (4% vs. 3%), upper respiratory tract infection (6% vs. 4%), pharyngitis (2% vs. 1%), and rhinitis (2% vs. 1%). Pediatric Hypertension Among children in clinical studies, 1 in 93 children age 1 to < 6 and 3 in 240 age 6 to < 17 experienced worsening renal disease.
The association between candesartan and exacerbation of the underlying condition could not be excluded. Heart Failure The adverse event profile of ATACAND in adult heart failure patients was consistent with the pharmacology of the drug and the health status of the patients. In the CHARM program, comparing ATACAND in total daily doses up to 32 mg once daily (n=3803) with placebo (n=3796), 21.0% of patients discontinued ATACAND for adverse events vs. 16.1% of placebo patients.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions were identified during post-approval use of ATACAND. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following have been very rarely reported in post-marketing experience: Digestive: Abnormal hepatic function and hepatitis.
Hematologic: Neutropenia, leukopenia, and agranulocytosis. Immunologic: Angioedema Metabolic and Nutritional Disorders: Hyperkalemia, hyponatremia. Respiratory System Disorders: Cough. Skin and Appendages Disorders: Pruritus, rash and urticaria. Rare reports of rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary ATACAND can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.
When pregnancy is detected, discontinue ATACAND as soon as possible. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death.
Pregnant women with hypertension should be carefully monitored and managed accordingly. Pregnant women with chronic heart failure are at increased risk for preterm birth. Stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester. Heart failure may worsen with pregnancy and may lead to maternal death.
Closely monitor pregnant patients for destabilization of their heart failure. Fetal/Neonatal Adverse Reactions Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension and death.
In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, based on the week of pregnancy.
Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. If oligohydramnios is observed, consider alternative drug treatment. Closely observe infants with histories of in utero exposure to ATACAND for hypotension, oliguria, hyperkalemia or other symptoms of renal impairment [see Use in Specific Populations (8.4)].
In neonates with a history of in utero exposure to ATACAND, if oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and replacing renal function. Animal Data Oral doses ≥10 mg of candesartan cilexetil/kg/day administered to pregnant rats during late gestation and continued through lactation were associated with reduced survival and an increased incidence of hydronephrosis in the offspring.
The 10-mg/kg/day dose in rats is approximately 2.8 times the maximum recommended daily human dose (MRHD) of 32 mg on a mg/m 2 basis (comparison assumes human body weight of 50 kg). Candesartan cilexetil is toxic to rabbits. When given to pregnant rabbits at an oral dose of 3 mg/kg/day (approximately 1.7 times the MRHD on a mg/m 2 basis), candesartan cilexetil caused maternal toxicity (decreased body weight and death) but, in surviving dams, had no adverse effects on fetal survival, fetal weight, or external, visceral, or skeletal development.
No maternal toxicity or adverse effects on fetal development were observed when oral doses up to 1000 mg of candesartan cilexetil/kg/day (approximately 138 times the MRHD on a mg/m 2 basis) were administered to pregnant mice.
Mechanism of action
12.1 Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.
Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathways for angiotensin II synthesis. There is also an AT 2 receptor found in many tissues, but AT 2 is not known to be associated with cardiovascular homeostasis.
Candesartan has much greater affinity (>10,000-fold) for the AT 1 receptor than for the AT 2 receptor. Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE.
Because candesartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Candesartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of candesartan on blood pressure.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Candesartan inhibits the pressor effects of angiotensin II infusion in a dose-dependent manner. After 1 week of once daily dosing with 8 mg of candesartan cilexetil, the pressor effect was inhibited by approximately 90% at peak with approximately 50% inhibition persisting for 24 hours. Plasma concentrations of angiotensin I and angiotensin II, and plasma renin activity (PRA), increased in a dose-dependent manner after single and repeated administration of candesartan cilexetil to healthy subjects, hypertensive, and heart failure patients.
ACE activity was not altered in healthy subjects after repeated candesartan cilexetil administration. The once-daily administration of up to 16 mg of candesartan cilexetil to healthy subjects did not influence plasma aldosterone concentrations, but a decrease in the plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was administered to hypertensive patients.
In spite of the effect of candesartan cilexetil on aldosterone secretion, very little effect on serum potassium was observed. Hypertension Adults In multiple-dose studies with hypertensive patients, there were no clinically significant changes in metabolic function, including serum levels of total cholesterol, triglycerides, glucose, or uric acid.
In a 12-week study of 161 patients with non-insulin-dependent (type 2) diabetes mellitus and hypertension, there was no change in the level of HbA 1c. Heart Failure In heart failure patients, candesartan ≥ 8 mg resulted in decreases in systemic vascular resistance and pulmonary capillary wedge pressure.
Pharmacokinetics
Metabolism and Excretion Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.
Total plasma clearance of candesartan is 0.37 mL/min/kg, with a renal clearance of 0.19 mL/min/kg.
When candesartan is administered orally, about 26% of the dose is excreted unchanged in urine.
Biliary excretion contributes to the elimination of candesartan.
Candesartan is mainly excreted unchanged in urine and feces (via bile).
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Distribution The volume of distribution of candesartan is 0.13 L/kg. Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells. The protein binding is constant at candesartan plasma concentrations well above the range achieved with recommended doses. In rats, it has been demonstrated that candesartan crosses the blood-brain barrier poorly, if at all.
It has also been demonstrated in rats that candesartan passes across the placental barrier and is distributed in the fetus. Metabolism and Excretion Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.
Total plasma clearance of candesartan is 0.37 mL/min/kg, with a renal clearance of 0.19 mL/min/kg. When candesartan is administered orally, about 26% of the dose is excreted unchanged in urine. Following an oral dose of 14 C-labeled candesartan cilexetil, approximately 33% of radioactivity is recovered in urine and approximately 67% in feces.
Following an intravenous dose of 14 C-labeled candesartan, approximately 59% of radioactivity is recovered in urine and approximately 36% in feces. Biliary excretion contributes to the elimination of candesartan. Adults Candesartan cilexetil is rapidly and completely bioactivated by ester hydrolysis during absorption from the gastrointestinal tract to candesartan, a selective AT 1 subtype angiotensin II receptor antagonist.
Candesartan is mainly excreted unchanged in urine and feces (via bile). It undergoes minor hepatic metabolism by O-deethylation to an inactive metabolite. The elimination half-life of candesartan is approximately 9 hours. After single and repeated administration, the pharmacokinetics of candesartan are linear for oral doses up to 32 mg of candesartan cilexetil.
Candesartan and its inactive metabolite do not accumulate in serum upon repeated once-daily dosing. Following administration of candesartan cilexetil, the absolute bioavailability of candesartan was estimated to be 15%. After tablet ingestion, the peak serum concentration (C max) is reached after 3 to 4 hours. Food with a high fat content does not affect the bioavailability of candesartan after candesartan cilexetil administration.
Pediatrics In children 1 to 17 years of age, plasma levels are greater than 10–fold higher at peak (approximately 4 hours) than 24 hours after a single dose. Children 1 to < 6 years of age, given 0.2 mg/kg had exposure similar to adults given 8 mg. Children > 6 years of age had exposure similar to adults given the same dose.
The pharmacokinetics (C max and AUC) were not modified by age, sex or body weight. Candesartan cilexetil pharmacokinetics have not been investigated in pediatric patients less than 1 year of age. From the dose-ranging studies of candesartan cilexetil, there was a dose related increase in plasma candesartan concentrations.
The renin-angiotensin system (RAS) plays a critical role in kidney development. RAS blockade has been shown to lead to abnormal kidney development in very young mice. Children < 1 year of age must not receive ATACAND. Administering drugs that act directly on the renin-angiotensin system (RAS) can alter normal renal development.
Geriatric and Sex The pharmacokinetics of candesartan have been studied in the elderly (≥ 65 years) and in both sexes. The plasma concentration of candesartan was higher in the elderly (C max was approximately 50% higher, and AUC was approximately 80% higher) compared to younger subjects administered the same dose. The pharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite did not accumulate in the serum of these subjects upon repeated, once-daily administration.
No initial dosage adjustment is necessary [see Dosage and Administration (2.1)]. There is no difference in the pharmacokinetics of candesartan between male and female subjects. Renal Insufficiency In hypertensive patients with renal insufficiency, serum concentrations of candesartan were elevated. After repeated dosing, the AUC and C max were approximately doubled in patients with severe renal impairment (creatinine clearance <30 mL/min/1.73 m²) compared to patients with normal kidney function.
The pharmacokinetics of candesartan in hypertensive patients undergoing hemodialysis are similar to those in hypertensive patients with severe renal impairment. Candesartan cannot be removed by hemodialysis. No initial dosage adjustment is necessary in patients with renal insufficiency [see Dosage and Administration (2.1)].
In heart failure patients with renal impairment, AUC 0-72h was 36% and 65% higher in mild and moderate renal impairment, respectively. C max was 15% and 55% higher in mild and moderate renal impairment, respectively. Pediatrics ATACAND pharmacokinetics have not been determined in children with renal insufficiency. Hepatic Insufficiency The pharmacokinetics of candesartan were compared in patients with mild and moderate hepatic impairment to matched healthy volunteers following a single oral dose of 16 mg candesartan cilexetil.
The increase in AUC for candesartan was 30% in patients with mild hepatic impairment (Child-Pugh A) and 145% in patients with moderate hepatic impairment (Child-Pugh B). The increase in C max for candesartan was 56% in patients with mild hepatic impairment and 73% in patients with moderate hepatic impairment. The pharmacokinetics after candesartan cilexetil administration have not been investigated in patients with severe hepatic impairment.
No initial dosage adjustment is necessary in patients with mild hepatic impairment. In hypertensive patients with moderate hepatic impairment, consideration should be given to initiation of ATACAND at a lower dose [see Dosage and Administration (2.1)]. Heart Failure The pharmacokinetics of candesartan were linear in patients with heart failure (NYHA class II and III) after candesartan cilexetil doses of 4, 8, and 16 mg.
After repeated dosing, the AUC was approximately doubled in these patients compared with healthy, younger patients. The pharmacokinetics in heart failure patients is similar to that in healthy elderly volunteers [see Dosage and Administration (2.3)].
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. ATACAND · ANI Pharmaceuticals, Inc. [US FDA-approved label, version 5, December 22, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94a59260-d2b6-464a-b5b9-bbc599e57e10
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .